Real-world treatment patterns and outcomes in metastatic clear cell renal cell carcinoma following immune checkpoint inhibitor progression (2018-2023).
Immune checkpoint inhibitors (ICI) have become standard of care for renal cell carcinoma (RCC) in the adjuvant, first-line and pre-treated settings. However, treatment patterns and outcomes of patients with RCC that progresses following ICI treatment are not well characterized.
Immune checkpoint inhibitors (ICI) have become standard of care for renal cell carcinoma (RCC) in the adjuvant, first-line and pre-treated settings. However, treatment patterns and outcomes of patients with RCC that progresses following ICI treatment are not well characterized.
What the study was
- Study design
- Cohort/Observational Study
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Oncologist
Why it surfaced
Matched watchlist topic 'Rare diseases with high unmet need'. Study design: Cohort/Observational Study. Score: 9/10 (N:3, R:3, D:1, P:2).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.